Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Mobidiag has developed and commercialized molecular diagnostic platforms—Novodiag® for rapid multiplexed near-patient testing and Amplidiag® for high-throughput laboratory diagnostics. Their solutions enable fast identification of pathogens responsible for gastrointestinal, respiratory, healthcare-associated infections, sepsis, and antimicrobial resistance. The company was acquired by Hologic in June/July of 2021 for approximately €668 million (~$795 million). In calendar year 2020 they generated about $42 million in revenue. Their technologies are used across Europe with a focus on rapid turnaround times to improve patient care.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Mobidiag.